Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Daniel, Peter Prof. Dr. (1) Leisegang, Matthias Prof. Dr. rer. nat. (1) Lusatis, Simone (1) Pezzutto, Antonio Prof. Dr. (2) Selbach, Matthias Prof. Dr. (2) Uckert, Wolfgang Prof. Dr. (1) Willimsky, Gerald Dr. (1) Wollert-Wulf, Brigitte (2) (-) Blankenstein, Thomas Prof. Dr. (10) (-) Janz, Martin Dr. (4) (-) Mathas, Stephan Dr. (4) (-) Biologie maligner Lymphome (5) Genetik und Genomik von Herz- Kreislauferkrankungen (1) (-) Molekulare Immunologie und Gentherapie (10) Translationale Onkologie solider Tumore (1) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) (-) 1997 (9) 1998 (9) 1999 (3) 2000 (9) 2001 (6) 2002 (10) 2003 (12) 2004 (11) 2005 (13) (-) 2006 (6) 2007 (9) 2008 (9) 2009 (6) 2010 (10) 2011 (9) 2012 (8) 2013 (14) 2014 (6) 2015 (8) 2016 (7) 2017 (11) 2018 (5) 2019 (8) 2020 (6) 2021 (9) 2022 (13) 2023 (14) 2024 (4) 15 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Janz, Martin Dr.Mathas, Stephan Dr.Biologie maligner LymphomeMolekulare Immunologie und Gentherapie 19972006 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas 01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken 01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert 15. Oktober 1997 / J Immunol Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis P.T. Daniel A. Kroidl S. Cayeux R.C. Bargou T. Blankenstein B. Doerken 15. Juli 1997 / J Immunol Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte- macrophage colony-stimulating factor gene-modified tumor cells Z. Qin G. Noffz M. Mohaupt T. Blankenstein 01. Januar 1997 / Eur J Immunol Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency S. Cayeux G. Richter C. Becker C. Beck A. Aicher A. Pezzutto B. Doerken T. Blankenstein 01. Januar 1997 / Exp Hematol Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells A. Aicher J. Westermann S. Cayeux G. Willimsky K. Daemen T. Blankenstein W. Uckert B. Doerken A. Pezzutto Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken
01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
15. Oktober 1997 / J Immunol Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis P.T. Daniel A. Kroidl S. Cayeux R.C. Bargou T. Blankenstein B. Doerken
15. Juli 1997 / J Immunol Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte- macrophage colony-stimulating factor gene-modified tumor cells Z. Qin G. Noffz M. Mohaupt T. Blankenstein
01. Januar 1997 / Eur J Immunol Lack of correlation between rejection of tumor cells co-expressing interleukin 2 and B7.1 and vaccine efficiency S. Cayeux G. Richter C. Becker C. Beck A. Aicher A. Pezzutto B. Doerken T. Blankenstein
01. Januar 1997 / Exp Hematol Successful retroviral mediated transduction of a receptor gene in human dendritic cells: feasibility of therapy with gene-modified antigen presenting cells A. Aicher J. Westermann S. Cayeux G. Willimsky K. Daemen T. Blankenstein W. Uckert B. Doerken A. Pezzutto